Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity.

ABSTRACT: The standard of care in high-grade gliomas has remained unchanged in the past 20 years. Efforts to replicate effective immunotherapies in non-cranial tumors have led to only modest therapeutical improvements for patients with glioma. Here, we demonstrate that intratumoral (i.t.) administration of recombinant interleukin-12 (rIL-12) promotes local cytotoxic CD8^POS T cell accumulation and conversion into an effector-like state, resulting in a dose-dependent survival benefit in preclinical glioblastoma (GB) mouse models. This tumor-reactive CD8 T cell response is further supported by intratumoral rIL-12-sensing dendritic cells (DCs) and is accompanied by the co-stimulatory receptor 4-1BB expression in both cell types. Given that DCs and CD8^POS T cells are functionally su

SUBMITTER: Lunavat TR 

PROVIDER: S-EPMC12500232 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature